Publicaties
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda Instituut voor Tropische Geneeskunde Universiteit Antwerpen
SETTING: In 2005, in response to the increasing prevalence of rifampicin-resistant tuberculosis (RR -TB) and poor treatment outcomes, Rwanda initiated the programmatic management of RR-TB, including expanded access to systematic rifampicin drug suscep-tibility testing (DST) and standardised treatment.
OBJECTIVE: To describe trends in diagnostic and treatment delays and estimate their effect on RR-TB mortality.
DESIGN: ...
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century Universiteit Antwerpen KU Leuven Instituut voor Tropische Geneeskunde
A pseudo-outbreak of pre-XDR TB in Kinshasa Instituut voor Tropische Geneeskunde Universiteit Antwerpen KU Leuven
Fluoroquinolones are the core drugs for management of multidrug-resistant tuberculosis (MDR-TB). Molecular drug susceptibility testing methods have considerable advantages for scaling up programmatic management and surveillance of drug-resistant TB. We describe misidentification of fluoroquinolone resistance by the GenoType®MTBDRsl (MTBDRsl, Hain Lifescience GmbH, Nehren, Germany) Line Probe Assay (LPA) encountered during a feasibility and ...
Predictors of rifampicin-resistant tuberculosis mortality among HIV-coinfected patients in Rwanda Instituut voor Tropische Geneeskunde Universiteit Antwerpen
Tuberculosis (TB), including multidrug-resistant (MDR; i.e., resistant to at least rifampicin and isoniazid)/rifampicin-resistant (MDR/RR) TB, is the most important opportunistic infection among people living with HIV (PLHIV). In 2005, Rwanda launched the programmatic management of MDR/RR-TB. The shorter MDR/RR-TB treatment regimen (STR) has been implemented since 2014. We analyzed predictors of MDR/RR-TB mortality, including the effect of ...